Literature DB >> 33106270

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.

Andrea Calcagno1, Ivano Dal Conte2, Dario Cattaneo3, Roberto Testi2, Massimiliano Mistrangelo4, Cristina Gervasoni5, Amedeo de Nicolò6, Stefano Bonora7, Antonio D'Avolio6, Giovanni Di Perri7.   

Abstract

Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.
Copyright © 2020 American Society for Microbiology.

Entities:  

Year:  2020        PMID： 33106270      PMCID： PMC7927807          DOI： 10.1128/AAC.01902-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir.

Authors:  Cristina Gervasoni; Dario Cattaneo; Chiara Resnati; Diletta Pezzani; Agostino Riva
Journal:  Eur J Clin Pharmacol       Date:  2017-03-06       Impact factor: 2.953

Review 2.  The Effect of Bariatric Surgery on Patients with HIV Infection: a Literature Review.

Authors:  Khalid Akbari; Robin Som; Marianne Sampson; Syed Hussain Abbas; James Ramus; Greg Jones
Journal:  Obes Surg       Date:  2018-08       Impact factor: 4.129

3.  Considerations for Using the HIRI-MSM Screening Tool to Identify MSM Who Would Benefit Most From PrEP.

Authors:  James Wilton; Sharmistha Mishra; Darrell H S Tan
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

4.  A Comparison of Tenofovir Predose Concentrations in Generic Pre-exposure Prophylaxis Formulations: A Short Communication.

Authors:  Dario Cattaneo; Cristina Gervasoni; Pietro Vinti; Sara Baldelli; Marta Fusi; Donatello Zagato; Anna De Bona; Elisa Suardi; Simona Bossolasco; Giuseppe Ancona; Roberto Rossotti; Massimo Cernuschi
Journal:  Ther Drug Monit       Date:  2020-08       Impact factor: 3.681

Review 5.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

6.  Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Authors:  Peter L Anderson; Albert Y Liu; Jose R Castillo-Mancilla; Edward M Gardner; Sharon M Seifert; Cricket McHugh; Theresa Wagner; Kayla Campbell; Mary Morrow; Mustafa Ibrahim; Susan Buchbinder; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome.

Authors:  P Timothy Pollak; Gavin R Sun; Richard B Kim
Journal:  Can J Cardiol       Date:  2017-12-27       Impact factor: 5.223

8.  HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Authors:  Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

9.  Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.

Authors:  Jennifer Velloza; Peter Bacchetti; Craig W Hendrix; Pamela Murnane; James P Hughes; Maoji Li; Marcel E Curlin; Timothy H Holtz; Sharon Mannheimer; Mark A Marzinke; K Rivet Amico; Albert Liu; Estelle Piwowar-Manning; Susan H Eshleman; Bonnie J Dye; Monica Gandhi; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

10.  Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.

Authors:  Ellen White; David T Dunn; Monica Desai; Mitzy Gafos; Peter Kirwan; Ann K Sullivan; Amanda Clarke; Sheena McCormack
Journal:  Sex Transm Infect       Date:  2019-03-27       Impact factor: 3.519
View more
  1 in total

Review 1.  Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.

Authors:  Leena Zino; Jurjen S Kingma; Catia Marzolini; Olivier Richel; David M Burger; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2022-04-11       Impact factor: 5.577
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.